Lu Meiqi, Zhang Ting, Lu Zhen, Wang Wei, Chen Ting, Cao Zhiqun
The First Clinical College, Shandong University of Traditional Chinese Medicine.
Department of Pharmacy, Shandong Rehabilitation Hospital.
Medicine (Baltimore). 2020 Jul 10;99(28):e21219. doi: 10.1097/MD.0000000000021219.
The incidence of ulcerative colitis (UC) is increasing year by year worldwide, and it is listed as one of the refractory diseases by World Health Organization. In addition to typical intestinal manifestations such as abdominal pain, diarrhea, mucus, pus, and bloody stool, it can also accompany multiorgan and multisystem extraintestinal manifestations, seriously affecting the life and work of patients. Furthermore, UC patients with a tremendous psychological pressure and affects their physical and mental health. In recent years, many complementary and alternative therapies have been used for treatment of UC, but only pair-wised drugs have been evaluated in the traditional meta-analyses and some results are inconsistent. Consequently, it is essential to propose a protocol for systematic review and meta-analysis to discuss the efficacy and safety of complementary and alternative therapies in the treatment of UC.
We will search Chinese and English databases comprehensively and systematically from the establishment of databases to May 2020, free of language or publication restrictions. All randomized controlled trials on complementary and alternative therapies for UC will be included. Two researchers will independently screen titles, abstracts, full texts, and extract data, then assess the bias risk of each study. We will conduct pairwise meta-analyses and Bayesian network meta-analyses to the relative outcomes of the efficacy and safety. Data analysis will use STATA and WinBUGs 1.4.3 software in this meta-analysis.
This study will evaluate the efficacy and safety of complementary and alternative therapies for UC based on changes in symptoms, clinical efficacy, quality of life and adverse events.
This study will provide evidence for whether complementary and alternative therapies are beneficial to the treatment of UC. In order to provide reliable evidence-based medicine for clinical practice.
INPLASY202060015.
全球范围内，溃疡性结肠炎（UC）的发病率逐年上升，它被世界卫生组织列为难治性疾病之一。除了腹痛、腹泻、黏液、脓血便等典型肠道表现外，它还可伴有多器官、多系统的肠外表现，严重影响患者的生活和工作。此外，UC患者心理压力巨大，影响其身心健康。近年来，许多补充和替代疗法已被用于治疗UC，但在传统的荟萃分析中仅对成对药物进行了评估，且一些结果并不一致。因此，有必要提出一项系统评价和荟萃分析方案，以探讨补充和替代疗法治疗UC的疗效和安全性。
我们将全面、系统地检索中文和英文数据库，检索时间从数据库建立至2020年5月，不受语言或发表限制。纳入所有关于UC补充和替代疗法的随机对照试验。两名研究人员将独立筛选标题、摘要、全文并提取数据，然后评估每项研究的偏倚风险。我们将对疗效和安全性的相关结果进行成对荟萃分析和贝叶斯网络荟萃分析。本荟萃分析将使用STATA和WinBUGs 1.4.3软件进行数据分析。
本研究将基于症状变化、临床疗效、生活质量和不良事件评估UC补充和替代疗法的疗效和安全性。
本研究将为补充和替代疗法是否有利于UC治疗提供证据。以便为临床实践提供可靠的循证医学依据。
INPLASY注册号：INPLASY202060015。
